Reporting from ELCC 2019 in Geneva, J. Wolf comments on the importance of searching for actionable genetic aberrations in NSCLC. He elaborates upon different gene fusions and in particular TRK fusion in terms of identifying patients who could benefit from effective new targeted therapies.
ELCC 2019 Highlight: Targeting fusions in Lung Cancer